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Abstract: A common irreversible adverse effect of life-saving
anticancer treatments is loss of gonadal endocrine function
and fertility, calling for a need to focus on post-treatment
quality of life. Here, we investigated the use of poly(ethylene
glycol)-vinyl sulfone (PEG-VS) based capsules to support syn-
geneic donor ovarian tissue for restoration of endocrine func-
tion in mice. We designed a dual immunoisolating capsule
(PEG-Dual) by tuning the physical properties of the PEG
hydrogels and combining proteolytically degradable and non-
degradable layers to meet the numerous requirements for
encapsulation and immunoisolation of ovarian tissue, such
as nutrient diffusion and tissue expansion. Tuning the com-
ponents of the PEG-Dual capsule to have similar physical
properties allowed for concentric encapsulation. Upon
implantation, the PEG-based capsules supported ovarian
tissue survival and led to a significant decrease in follicle
stimulating hormone levels 60 days postimplantation. Mice
that received the implants resumed regular estrous cycle
activity and follicle development in the implanted grafts. The
PEG-Dual capsule provided an environment conducive for tis-
sue survival, while providing a barrier to the host environ-
ment. This study demonstrated for the first time that
immunoisolating PEG-VS capsules can support ovarian follic-
ular development resulting in the restoration of ovarian
endocrine function and can be applied to future allogeneic
studies. VC 2018 Wiley Periodicals, Inc. J Biomed Mater Res Part A:
106A: 1381–1389, 2018.
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INTRODUCTION
Loss of gonadal endocrine function and fertility in cancer
patients undergoing chemo- and radiotherapy is a common
irreversible consequence of these lifesaving therapies.1–6
With improved survival rates of up to 80%, survivors of
childhood cancer are a rapidly growing population, necessi-
tating a shift in focus from simply survival to quality of life
post-treatment. Abnormal puberty, osteopenia, muscle wast-
ing, cardiovascular disease, frailty, sterility, and risk of pre-
mature death all stem from impaired gonadal function.7–10
The restoration of reproductive and endocrine function is
uniquely challenging due to the limited and nonrenewable
ovarian reserve. Cryopreservation of ovarian or testicular
tissue obtained prior to exposure to gonadotoxic treatments,
with subsequent implantation in survivors can restore both
fertility and endocrine function, but the risk of
reintroducing malignant cells present in the ovarian tissue
limits its translation to the clinic.11–13 To avoid this risk,
implantation of the donor ovarian tissue encapsulated in an
immunoisolating capsule has the potential to restore ovar-
ian endocrine function by secreting the gonadal hormones,
while eliminating the risk of reseeding cancer cells and the
need for immunosuppressant therapy.
Implantation of hormone secreting cells, such as pancre-
atic islets, in immunoisolating capsules has been investi-
gated for treating type I diabetes.14–17 For this purpose,
hormone secreting cells are encapsulated in a semiperme-
able membrane that prevents or attenuates the interaction
between the encapsulated allogeneic cells or tissue and the
host immune system, while allowing diffusion of nutrients
and waste.18 Ovarian follicles, which are the functional hor-
mone secreting units of the ovary, are similar to islets in
Corrrespondence to: A. Shikanov; e-mail: shikanov@umich.edu
Contract grant sponsor: The Hartwell Foundation; contract grant numbers: 14-00981, 14-PAF00981
Contract grant sponsor: National Institute of Biomedical Imaging and Bioengineering (A.S. and M.C.); contract grant number: R01 EB022033
Contract grant sponsor: National Science Foundation Graduate Research Fellowship Program; contract grant number: DGE 1256260
VC 2018 WILEY PERIODICALS, INC. 1381
that they synthesize and secrete hormones in response to
circulating stimuli, in this case follicle stimulating hormone
(FSH); however, unlike islets, ovarian follicles are dynamic
in growth. At the beginning of each cycle only a small por-
tion of follicles activates and enters the growing pool. The
growing follicles undergo a multiple fold volumetric expan-
sion, which when encapsulated in an immunoisolating cap-
sule must be accommodated by a degradable matrix that
mirrors and allows the follicle expansion. Furthermore, fol-
licles are avascular and relatively resistant to hypoxia,
allowing them to survive and function with diffusion
through the encapsulating matrix being the only mechanism
to supply oxygen and nutrients.
We have reported earlier that hydrogels prepared with
poly(ethylene glycol) vinyl sulfone (PEG-VS) and crosslinked
with proteolytically sensitive peptides supported follicle
development in vitro and in vivo.19,20 For the purposes of
immunoisolation, we investigated whether the tunable prop-
erties of PEG hydrogels and inert nonimmunogenic interface
with the host21,22 can match the requirements to allow fol-
licle expansion while preventing inﬁltration of the cells
from the host and immune reaction. We encapsulated synge-
neic ovarian tissue in three different PEG-VS constructs:
a nondegradable photo-polymerized PEG-VS hydrogel
(PEG-NPD), a proteolytically degradable PEG-VS hydrogel
(PEG-PD), and a dual PEG-VS hydrogel (PEG-Dual) construct
containing a proteolytically degradable PEG-VS core with a
nondegradable PEG-VS shell (Scheme 1). The objectives of
this study were to: (1) answer the question whether the
viscoelastic properties of a nondegradable PEG-VS hydrogel
are sufﬁcient to allow follicle expansion; (2) create a dual
construct with a degradable core and nondegradable shell
with controlled physical properties to match follicle expan-
sion; and (3) to identify the PEG-VS-based hydrogel con-
struct that supports ovarian tissue survival and function,
leading to ovarian endocrine function restoration.
MATERIALS AND METHODS
Hydrogel preparation
To form the PEG-NPD hydrogel network, four-arm PEG-VS
(20 kDa, JenKem Technology, Beijing, China) is dissolved in
a solution containing sterile Dulbecco’s phospate buffered
saline (DPBS) (pH 7.4) and 0.4 mg/100 mL Irgacure 2959
[Ciba, Switzerland, molecular weight (MW)5 224.3] to cre-
ate a concentration of 5% w/v. Irgacure 2959 is the photo-
initiator of choice as it has been demonstrated to be
biocompatible across multiple cell lines.23 Furthermore,
N-vinyl-2-pyrrolidone (NVP) (Sigma-Aldrich, St. Louis) is
added at a ﬁnal concentration of 0.1%, as NVP has been
demonstrated to enhance gelation without impacting cyto-
compatibility.24 To induce cross-linking, the precursor solu-
tion is exposed to ultraviolet (UV) light at a constant
intensity (1090 mW/cm2 at a distance of 4 cm).
The PEG-PD hydrogels are formed through Michael-
type addition through the inclusion of a plasmin sensitive tri-
functional peptide sequence (Ac-GCYK#NSGCYK#NSCG,
MW 1525.69 g/mol, >90% Purity, CelTek, # indicates the
cleavage site) (YKNS). Brieﬂy, to prepare the gels, 8-arm PEG-
VS (40 kDa, JenKem Technology, Beijing, China) is dissolved
in an isotonic 4-(2-hydroxyethyl)-1-piperazineethanesulfonic
acid (HEPES) buffer (HEPES 0.05M, pH5 7.4) to create a
ﬁnal concentration of 5 or 10% w/v and YKNS was added,
such that the molar ratio of –SH and –VS groups was 1:1.
The PEG-Dual hydrogel construct contains a proteolyti-
cally degradable core with a nondegradable outer shell. To
manufacture the dual PEG hydrogel, a 4 mL degradable core
(5% w/v PEG-VS) is formed via the aforementioned tech-
nique for the degradable 8-arm PEG-VS hydrogel. Immedi-
ately after 5 min of gelation, the degradable hydrogel bead
is transferred over and placed in the center of a 10 mL bead
of the nondegradable precursor solution. The PEG-Dual con-
struct is then exposed to a constant intensity (1090
mW/cm2 at a distance of 4 cm) for 6 min creating the non-
degradable outer shell of the hydrogel (Scheme 1).
Swelling ratio
Five percent w/v PEG-NPD and PEG-PD hydrogels were
tested. The PEG-NPD gels were exposed to UV light for 6
min and were submerged in DPBS for 24 h. Similarly, the
PEG-PD gels formed for 5 min after the introduction of
YKNS; thereafter the reaction was quenched by submerging
the gels in DPBS and remained there for 24 h. After 24 h,
excess DPBS was removed and the swollen mass of the
hydrogels was obtained. Gels were then removed from solu-
tion and allowed to dry at room temperature. Larger vol-
umes were used to minimize error from weighing. The mass
swelling ratio (Qm) was determined by dividing the mass of
the swollen gels (Ms) by the mass of the dry gels (Md).
25
Rheology
The storage modulus (G0) and loss modulus (G00) was inves-
tigated for two PEG constructs—5% PEG-NPD and 5% PEG-
PD. The gels were prepared and swollen in DPBS overnight.
A TA HR-2 rheometer (TA Instruments) equipped with
20 mm parallel plates and a Peltier stage was used for this
purpose. To ensure the hydrogel was the same size as the
geometry, 1 mm thick hydrogel slabs were made and a
20 mm diameter disk was punched out. A constant strain
rate of 5% was kept for all samples and the storage modu-
lus was obtained by performing an angular frequency sweep
from 0.1 to 10 rad/s.
Ovariectomies in recipient mice
Before any surgical procedure, preemptive analgesics were
administered. To induce infertility, bilateral ovariectomies
were performed on 12–16 week-old adult female mice
(B6CBAF1). All procedures (PRO00005750) followed the
IACUC guidelines for survival surgery in rodents and the
IACUC Policy on Analgesic Use in Animals Undergoing
SCHEME 1. Representation of encapsulating ovarian tissue in a PEG-
Dual capsule with a PEG-PD core and PEG-NPD outer shell.
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Surgery. Brieﬂy, the female was anesthetized by isoﬂurane,
Carprofen (Rimadyl, Zoetis) was administered, and a midline
incision was made in the abdominal wall. Using an abdomen
retractor, the intraperitoneal space was exposed, and the
ovaries were removed, leaving the remainder of the repro-
ductive tract. The muscle and skin layer of the abdominal
wall were closed with 5/0 absorbable sutures (AD Surgical).
The animal recovered in a clean warmed cage. Postsurgery,
animals received analgesia for at least 24 h or as needed.
Ovarian tissue encapsulation in PEG hydrogels
Ovaries were collected from 6 to 8 days old B6CBAF1 female
pups. These pups are genetically matched to the receiving
host. The collected ovaries were transferred to Leibovitz L-15
media (Sigma-Aldrich) and dissected into two pieces. The ovar-
ian tissue pieces were then transferred into maintenance
media [alpha-minimum essential medium (a-MEM)] and
placed into incubator set to 5% CO2. For encapsulation in
PEG-NPD, the ovarian tissue was transferred into a 10 lL
droplet of the precursor solution (5% w/v PEG-VS, .4% Irga-
cure 2959, 0.1% NVP) and exposed to UV light. For encapsula-
tion in the PEG-PD, the ovarian tissue was transferred into a
10 lL droplet of the plasmin sensitive trifunctional peptide
and PEG-VS precursors’ solution. The droplet was allowed to
crosslink for 5 min and then was quenched in maintenance
media. For the PEG-Dual hydrogel encapsulation, the tissue
was ﬁrst encapsulated in a 4 lL PEG-PD gel and was then
placed in the center of a 10 lL bead of PEG-NPD and exposed
to UV light. All constructs were imaged immediately after
encapsulation of the tissue.
Implantation of immunoisolating capsules in mice
To investigate the survival and function of the ovarian tissue
encapsulated in immunoisolation capsules we implanted
subcutaneously immunoisolating capsules in the ovariectom-
ized mice. Brieﬂy, a small incision was made on the dorsal
side of the anesthetized mice and two constructs (PEG-NPD,
PEG-PD, or PEG-Dual) with encapsulated ovarian tissue
were implanted subcutaneously and the skin was closed
using 5/0 absorbable sutures. The mice received analgesia
for at least 24 h after surgery or as needed. Mice were
euthanized at predetermined end time points (7, 30, and 60
days postoperation).
Serum hormone analysis
Blood was collected from the lateral tail vein at designated
time points with a 53/4 in. glass Pasteur pipette up to the
time of sacriﬁce. After collection, all samples were stored at
48C overnight, then centrifuged for 10 min at 10,000 rpm
and the collected serum was stored at 2208C. The samples
were analyzed for mouse FSH using a radio-immunoassay
(Ligand Assay and Analysis Core Facility, University of Vir-
ginia Center for Research in Reproduction). The core at the
University of Virginia used mouse FSH reference prepara-
tion AFP5308D for assay standards and mouse FSH antise-
rum (guinea pig; AFP-1760191) diluted to a ﬁnal
concentration of 1:400,000 as primary antibody. The sec-
ondary antibody is from Equitech-Bio, Inc. and was diluted
to a ﬁnal concentration of 1:25. The radio-immunoassay has
a sensitivity of 2.0 ng/mL and <0.5% cross-reactivity with
other pituitary hormones. When needed, the samples were
diluted 5–10-fold.
Evaluation of the regularity of estrous cycle
To assess estrous cycle cessation, vaginal cytology was per-
formed seven days after ovariectomy. After transplantation,
vaginal cytology was resumed 7 days postoperation and
was performed daily until sacriﬁce. The transition from leu-
kocytes to corniﬁed cells at least once a week was counted
as a resumed or continued cycle.
Histological analysis of the retrieved capsules and the
encapsulated tissue
Immediately after retrieval of the immunoisolating capsules
from mice, the capsules were ﬁxed in Bouin’s ﬁxative at 48C
overnight and transferred and stored in 70% ethanol at 48C.
Constructs encapsulating ovarian tissue were then proc-
essed, embedded in parafﬁn, serially sectioned at a 5 lm
thickness, and stained with hematoxylin and eosin. To deter-
mine the stage of follicular development, follicles were clas-
siﬁed as follows: follicles with one layer of squamous
granulosa cells around the oocyte were classiﬁed as primor-
dial follicles, a single layer of cuboidal granulosa cells—pri-
mary follicles, two or more layers of granulosa cells—a
secondary follicle, and follicles with an antral cavity were
classiﬁed as antral follicles.
Trichrome staining
After retrieval of the PEG constructs from the mice, the cap-
sules were ﬁxed in Bouin’s ﬁxative at 48C overnight and
transferred and stored in 70% ethanol at 48C. Hydrogels
were then processed, embedded in parafﬁn, serially sec-
tioned at a 5 lm thickness, and stained with Masson’s Tri-
chome 2000 Stain Kit (American Mastertech, Inc.). Capsule
thickness was quantiﬁed via Image J software.
Statistics
Statistical analysis was performed using the R software.
Two-sample t tests were used to evaluate changes in hor-
mone levels and differences in swelling ratio and storage
modulus between PEG constructs. The results were consid-
ered statistically signiﬁcant when p< 0.05.
RESULTS
Visco-elastic properties of PEG-VS hydrogels
To determine the physical properties of the PEG hydrogels
encapsulating the ovarian tissue, we measured the equilib-
rium mass swelling ratio and storage modulus of 5% PEG-
NPD and PEG-PD. We found that PEG-NPD, prepared
through free radical photo-polymerization chemistry, and
PEG-PD, prepared with thiol-ene Michael type addition
chemistry, had comparable swelling ratios [Fig. 1(A)]. The
Qm of PEG-PD hydrogels was 32.2, and the Qm of PEG-NPD
hydrogels was 30.2. Similarly to the swelling ratio, the stor-
age modulus for PEG-PD hydrogels was 2403 and 2876 Pa
for PEG-NPD [Fig. 1(B,C)]. Speciﬁcally important for the
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PEG-Dual capsule, similar swelling ratios and visco-elastic
properties of the two types of the hydrogels allow concen-
tric encapsulation of the PEG-PD as a core inside a PEG-
NPD shell without further modiﬁcation.
Encapsulation and subcutaneous implantation of
ovarian tissue
The ovarian tissue encapsulated in PEG-NPD, PEG-PD, or PEG-
Dual hydrogel was completely surrounded in the respective
hydrogel network [Fig. 2(A,D,G)]. For the PEG-Dual hydrogel,
the ovarian tissue was encapsulated in PEG-PD core, which
was surrounded by a PEG-NPD shell [Fig. 2(G)]. At the time of
sacriﬁce, the hydrogels were easily identiﬁed and retrieved
from the subcutaneous space. No difference in the appearance
of the different capsules was noted. Because of the inert and
nonfouling properties of PEG hydrogels, we observed minimal
interaction with the host tissue at the area around the
implanted capsules [Fig. 2(B,E,H)]. At the macroscopic evalua-
tion of the capsules, which were easily removed from the host,
the ovarian tissue was visible and fully encapsulated in the
center of the capsules. No signs of revascularization or cell
inﬁltration were observed, which was the anticipated result to
ensure efﬁcient immunoisolation [Fig. 2(C,F,I)].
Follicle development and growth in the
immunoisolation capsules
We performed histological analysis of the retrieved ovarian
tissue in immunoisolating capsules to investigate the growth
and development of the follicles, up to 60 days postimplan-
tation. After 7 days of implantation in the immunoisolating
capsule small primordial and primary follicles were found
in all the capsules [Fig. 3(A,D,G)]. After 30 days of implanta-
tion multiple large antral follicles developed in the ovarian
tissue implanted in PEG-PD and PEG-Dual, supporting our
initial hypothesis that proteolytic degradation was essential
to promote follicular growth [Fig. 3(B,H)]. We identiﬁed
multiple follicles in the PEG-NPD capsule after 30 and 60
days, yet the antral follicles failed to develop an antral cav-
ity, as demonstrated in Figure 3(F). Similar to the ﬁndings
at 30 days postimplantation, multiple growing and fully
developed antral follicles were observed in the ovarian tis-
sue implanted in PEG-PD and PEG-Dual, but not in PEG-
NPD. In agreement with our macroscopic ﬁndings, we did
not ﬁnd evidence of blood vessel inﬁltrating the implanted
tissue, which further conﬁrmed the barrier to the host by
the gels.
Restoration of ovarian endocrine function
In adult mice with healthy functioning ovaries the levels of
circulating FSH is below 20 ng/mL. After ovariectomy the
lack of negative feedback of estradiol, normally produced in
the ovarian follicles, results in increased levels of FSH that
can reach 100 ng/mL. Mice in all groups had the average
FSH level of 4–8 ng/mL before ovariectomy (n5 16 for
PEG-NPD, n5 11 for PEG-PD, n5 18 for PEG-Dual). After a
bilateral ovariectomy, FSH levels rose signiﬁcantly (p 
0.05) to an average of 55–71 ng/mL (n5 15 for PEG-NPD,
n512 for PEG-PD, and n5 16 for PEG-Dual). The rise in
FSH levels is the result of low levels of circulating estradiol,
conﬁrming that the ovaries were removed and the
hypothalamus-pituitary-gonadal (HPG) axis was disrupted.
Sixty days after mice received ovarian tissue encapsulated
in PEG-NPD (n5 6), PEG-PD (n5 7), or PEG-Dual hydrogel
(n5 11), FSH levels decreased signiﬁcantly from an average
of 64 ng/mL to an average of 34.8 (p5 0.0004), 30.5
(p50.028), and 34.3 ng/mL (p5 0.01), respectively [Fig.
4(A)], indicating the HPG axis was restored upon implanta-
tion in all the groups.
Estrous cycle restoration
Estrous cycle correlates with ovulation and lasts 4–5 days
in rodents. After ovariectomy the estrous cyclicity ceases,
which is determined by the absence of corniﬁed cells in the
vaginal secretions. Implantation of ovarian tissue in PEG-PD
restored cyclicity in 90% of the mice 1 week postimplanta-
tion, and in 100% by the second week [Fig. 4(B)]. Restora-
tion of cyclicity was delayed in mice that received the
implants in PEG-NPD and PEG-Dual with 60% of the mice
cycling 1 week after implantation, and reaching 100%
cyclicity by week 4. However, while 90% of the mice that
received ovarian implant in PEG-Dual capsule continued
cycling for 9 weeks, only 67% of the mice that received the
PEG-NPD capsule continued cycling after 7 weeks, which
correlates with the histological analysis and suggests that
the follicle growth was restricted in the nondegradable
capsules.
FIGURE 1. A: Swelling ratio (n5 5 for all compositions) and (B) stor-
age modulus of 5% PEG-PD (n53) and PEG-NPD (n54). (C) Illustra-
tion of storage modulus and loss modulus of 5% PEG-PD and 5%
PEG-NPD. All data reported (A,B) is mean6SD.
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Collagen deposition
After implantation for 30 and 60 days, PEG-PD, PEG-NPD,
and PEG-Dual exhibited a thin ﬁbrotic capsule around the
respective hydrogel [Fig. 5(A–F)]. There was no signiﬁcant
difference in the ﬁbrotic capsule thickness around the
immunoisolating capsules [Fig. 5(G)]. When comparing
ﬁbrotic capsule thickness from 30 to 60 days postimplan-
tation, there was no signiﬁcant difference in collagen depo-
sition (p<0.05), indicating the absence of a chronic
inﬂammatory response. Cell inﬁltration from the host or
cell migration from the encapsulated ovarian follicles was
not observed in the implants. Interestingly, cells were pres-
ent throughout the ﬁbrotic capsule around the degradable
hydrogel (PEG-PD) [Fig. 5(A)], but in the case of nonde-
gradable PEG, cells were concentrated in the narrow space
between the gel and the ﬁbrotic capsule. This ﬁnding may
indicate that a degradable gel induced a different reaction
with the innate immune cells compared to a nondegrad-
able gel.
DISCUSSION
This study investigated whether the PEG-based immunoiso-
lating capsules support the viability and function of encap-
sulated and implanted ovarian tissue for the purpose of
restoration of ovarian endocrine function in ovariectomized
mice. The results show for the ﬁrst time the development
and characterization of novel photo-polymerized and dual
PEG based hydrogel systems. We found that PEG-VS based
hydrogels support ovarian tissue and restore endocrine
function for at least 60 days. Future allogeneic studies in
mice and higher species will conﬁrm whether PEG-PD and
PEG-Dual constructs protect the tissue from being recog-
nized and/or destroyed by allo-immunity.
We designed the immunoisolating capsule by tuning the
physical properties of the PEG hydrogels and combining
degradable and nondegradable layers to meet the numerous
requirements for immunoisolation of ovarian tissue. For
example, the diffusion of nutrients was achieved with low
solid concentration and efﬁcient crosslinking density of the
FIGURE 2. Macroscopic images of PEG-VS hydrogels before and after implantation. (A) Ovarian tissue encapsulated in PEG-PD, (B) PEG-PD at
the time of sacrifice, (C) PEG-PD after removal, (D) Ovarian tissue encapsulated in PEG-NPD, (E) PEG-NPD at the time of sacrifice, (F) PEG-NPD
after removal, (G) Ovarian tissue encapsulated in PEG-Dual, (H) PEG-Dual at the time of sacrifice, (I) PEG-Dual after removal. White dotted circle
indicates the localization of the hydrogel on the mice. Solid black arrows indicate encapsulated ovarian tissue. Dashed black arrows indicate the
border of PEG-PD and solid white arrows indicate the border of PEG-NPD. Magnification 53 (A,D,G).
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network. The nondegradable layer of the PEG hydrogel cre-
ated a physical barrier between the host and the implant.
The proteolytic degradation in response to the cell-secreted
proteases from the encapsulated follicles allowed the volu-
metric expansion of ovarian tissue. Finally, the intermediate
stiffness and inertness of the PEG hydrogel caused minimal
inﬂammatory response at the interface of the capsule and
the host.
The strategy of encapsulating the tissue grafts in encap-
sulating devices allows oxygen and nutrients delivery via
diffusion through the hydrogel without the risk of exposure
to the immune cells. These properties may be useful to pre-
vent rejection of tissue allografts which inevitably occur
when the tissue is directly transplanted. The tunability of
PEG hydrogels allows excellent control over pore size of the
network formed around the encapsulated tissue. Ovarian tis-
sue encapsulated in PEG-PD, PEG-NPD and the PEG-Dual
capsule survived the encapsulation and the implantation for
60 days. The histological sections of the retrieved tissue
demonstrated no evidence of necrosis and appeared normal
with phenotypically healthy follicles. Further, in the dual
capsule we matched the swelling ratio and storage moduli
of each layer, which allowed us to coencapsulate several
layers of hydrogels having similar properties. The degrad-
able core around the encapsulated ovarian tissue sur-
rounded by a nondegradable shell interfacing with the host
isolated the tissue from the host environment, while still
allowing diffusion and promoting survival of the tissue.
Ovarian follicles exhibit dynamic growth during the hor-
monal phases, necessitating a need for a material with
viscoelastic properties that either degrades in response to
follicle secreted proteases or can mechanically withstand
the follicle expansion. Our previous study using alginate as
an immunoisolator for ovarian tissue demonstrated that the
viscous properties of alginate were insufﬁcient to support
the follicle expansion, and either excessively compressed the
FIGURE 3. Histological image of ovarian tissue encapsulated: in PEG-PD (A) showing primordial (*) and primary follicles (**) in 7 days implants
(n5 3 mice), (B), (C) showing secondary (***) and antral follicles (****) in 30 (n54 mice) and 60 day (n57 mice) implants, respectively, PEG-
NPD implants showing primordial and secondary follicles (D,E,F) after 7 (n58 mice), 30 (n5 4 mice) and 60 (n5 6 mice) days, respectively, and
PEG-Dual implants showing secondary (G) and antral (H,I) follicles in 7 (n53 mice), 30 (n5 4 mice) and 60 (n5 11 mice) day implants, respec-
tively. (P) indicates the encapsulating PEG hydrogel. “ac” indicates antral cavity. Magnification 103 (B,C,E), 203 (A,D,F,G,H,I).
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tissue or failed to maintain the protective layer.26 Shikanov
et al. demonstrated that a proteolytically degradable PEG-VS
hydrogel system was conducive for the development of
ovarian follicles as they can grow, mature, and respond to
circulating gonadotropins in culture.19 Here, we proposed to
encapsulate the ovarian tissue in viscoelastic PEG hydrogel
and determine whether the proteolytic degradation of
the matrix was essential for ovarian tissue survival and
function. When implanted in mice for 7, 30, and 60 days, all
PEG constructs supported ovarian tissue survival and sec-
ondary and antral follicles were present in the retrieved
implants. FSH levels in mice with ovarian tissue encapsu-
lated in PEG-NPD, PEG-PD, and PEG-Dual signiﬁcantly
decreased 60 days postimplantation compared to preim-
plantation levels (p< 0.05), indicating the reversal of the
ovariectomized phenotype and restoration of the ovarian
FIGURE 4. A: FSH levels of mice receiving ovarian tissue encapsulated in PEG-NPD, PEG-PD, and PEG-Dual before ovariectomy, after ovariec-
tomy, 4 weeks postimplantation, and sixty days postimplantation. An asterisk (*) denotes a significant difference (p< 0.05) between preovariec-
tomy levels and the designated group. Significance was determined by a two-sample t test. B: Cyclicity observed in mice implanted with D-PEG,
ND-PEG and PEG-Dual in the syngeneic model. Presence of a change between leukocytes and cornified cells at least once per week was deemed
continuation of estrous cycles.
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endocrine function. The restoration of the estrous cycle and
the decrease in FSH levels proved that the tissue encapsu-
lated in the construct responded to the circulating gonado-
tropins and the encapsulated follicles secreted estradiol
creating a negative feedback loop in the HPG axis. The histo-
logical evaluation of the encapsulated tissue indicated that
PEG-PD was superior in terms of supporting tissue viability
and function compared to PEG-NPD. PEG-PD degraded in
response to the secreted proteases from cells, providing a
supporting network without exerting a compressive force
back on the tissue in a way PEG-NPD does. However, PEG-
PD cannot solely serve as an efﬁcient immunoisolator and
eventually would degrade exposing the tissue to the host
immune system. Coencapsulation of a degradable PEG-PD
core in a nondegradable PEG-NPD shell demonstrated suc-
cessful restoration of ovarian endocrine function similar to
PEG-PD alone with the possibility for no risk of rejection. As
PEG-PD degrades over time, the outer layer of PEG-NPD is
crucial to protect the implanted tissue for allogeneic implan-
tations. The inclusion of a degradable core provides the bio-
mimetic microenvironment for the encapsulated ovarian
tissue while the PEG-NPD outer shell provides protection
from the immune cells in the host. In the current study, we
demonstrated that the ovarian tissue encapsulated in PEG-
Dual hydrogel remains healthy long-term and restoration of
endocrine function occurs as indicated by the continuation
of the estrous cycle. Corresponding to this observation we
observed a signiﬁcant decrease in FSH levels compared to
the preimplantation levels.
Synthetic biomaterials, such as PEG hydrogels, are an
attractive platform for protein and cell delivery because of
their low inﬂammatory index.21,22 PEG hydrogels are one of
the most commonly used synthetic materials for islet immu-
noisolation, for example. Multiple reports demonstrated that
islets encapsulated in PEG remained viable and maintained
normoglycemia.16–18,27 PEGylated membranes also protected
islets from cytokine induced inﬂammation and destruction
in vitro.15 Similarly, the implanted PEG-based capsules with
encapsulated ovarian tissue described here did not cause an
excessive inﬂammatory reaction. Our in vivo studies demon-
strated a thin collagen capsule formation, which correlates
with a minimal inﬂammatory response characteristic to the
inert properties of PEG hydrogels. Importantly, we did not
observe inﬁltration of cells or blood vessels from the host,
which further conﬁrmed the efﬁciency of the tested hydro-
gels as establishing a barrier between the tissue and the
host environment.
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